TrueBinding

TrueBinding Inc. is a clinical-stage biotherapeutic company dedicated to developing innovative monoclonal antibody therapeutics for a wide range of diseases with significant unmet medical needs. Their focus areas include neurodegenerative diseases like Alzheimer's, Parkinson's, and ALS, as well as stroke, metabolic disorders, oncology, and other areas. TrueBinding's proprietary platform technology enables them to rapidly develop and deliver highly specific and effective monoclonal antibodies, ushering in a new era of precision medicine.

Beyond their own research and development, TrueBinding offers comprehensive contract development and manufacturing services (CDMO) to other biopharmaceutical companies. These services span a wide range of capabilities, including cell line development, process development, formulation development, analytical services, cGMP manufacturing, clinical drug product logistics, and vivarium services. Their expertise and commitment to quality ensure that clients can accelerate their development timelines and bring innovative therapies to market faster and more cost-effectively.

TrueBinding is a clinical-stage biotherapeutic company dedicated to revolutionizing patient care through the development of novel monoclonal antibody therapeutics. They focus on addressing unmet medical needs in neurodegenerative and metabolic diseases, stroke, oncology, and other areas by rapidly developing and delivering highly specific and effective monoclonal antibodies. Their proprietary platform technology, the TrueBinding™ platform, enables them to accelerate the development and production of these life-changing therapies, ushering in a new era of precision medicine and improved patient outcomes.

TrueBinding promotes a culture of innovation and compassion, with a strong focus on patient care and scientific advancement. The company values collaboration and teamwork, evident in its diverse team of scientists, physicians, and drug developers. TrueBinding's commitment to improving patient outcomes is reflected in its dedication to developing groundbreaking therapies and providing access to investigational medications through its Expanded Access Program.